高压氧治疗非动脉炎性中央视网膜动脉阻塞的回顾性对比分析：来自两个三级医疗中心的数据。
Hyperbaric oxygen treatment for non-arteritic central retinal artery occlusion retrospective comparative analysis from two tertiary medical centres.
机构信息
Department of Ophthalmology, Shamir Medical Center, Zerifin, Israel.
Department of Ophthalmology, Soroka Medical Center, Be'ersheba, Israel.
出版信息
Eye (Lond). 2022 Jun;36(6):1261-1265. doi: 10.1038/s41433-021-01617-8. Epub 2021 Jun 17.
OBJECTIVES
To compare the visual outcome of patients treated for non-arthritic central retinal artery occlusion (CRAO) in a medical centre that uses hyperbaric oxygen therapy (HBOT) as part of the standard of care (SOC) to medical centres that does not.
METHODS
The study included data from two tertiary medical centres. The medical records of all patients diagnosed with non-arthritic CRAO without a patent cilioretinal artery between January 2010 and December 2018 in two tertiary medical centres were reviewed.
RESULTS
One hundred and twenty-one patients were treated by HBOT and 23 patients received only SOC. In the HBOT group, best-corrected visual acuity (BCVA) improved from 2.89 ± 0.98 logMAR at presentation to 2.15 ± 1.07 logMAR upon the end of HBOT (P < 0.001), while the SOC group had no significant improvement, from 3.04 ± 0.82 logMAR at presentation to 2.80 ± 1.50 logMAR (P = 0.24). With adjustment for age, gender, and the duration of symptoms, final BCVA in the HBOT group was significantly better compared to the control group (P = 0.023). Rates of patients achieving vision of 20/200 or better were similar between groups (17.4% vs. 19.8%, P = 0.523).
CONCLUSION
Utilizing HBOT as part of the SOC for CRAO improves the final visual outcome. HBOT is safe and can be implemented, if available, as part of SOC in all tertiary medical centres.
目的
比较在使用高压氧治疗（HBOT）作为标准治疗（SOC）的医疗中心与不使用该方法的医疗中心治疗非关节炎性中央视网膜动脉阻塞（CRAO）患者的视力结果。
方法
该研究纳入了来自两个三级医疗中心的数据。对这两个三级医疗中心 2010 年 1 月至 2018 年 12 月期间所有诊断为非关节炎性 CRAO 且无睫状视网膜动脉通畅的患者的病历进行了回顾。
结果
121 例患者接受 HBOT 治疗，23 例患者仅接受 SOC 治疗。在 HBOT 组，最佳矫正视力（BCVA）从就诊时的 2.89±0.98 logMAR 提高到 HBOT 结束时的 2.15±1.07 logMAR（P<0.001），而 SOC 组无显著改善，从就诊时的 3.04±0.82 logMAR 提高到 2.80±1.50 logMAR（P=0.24）。在校正年龄、性别和症状持续时间后，HBOT 组的最终 BCVA 明显优于对照组（P=0.023）。两组达到 20/200 或更好视力的患者比例相似（17.4% vs. 19.8%，P=0.523）。
结论
将 HBOT 作为 CRAO SOC 的一部分可改善最终视力结果。如果有条件，HBOT 可作为所有三级医疗中心 SOC 的一部分安全实施。
Zotero 插件